ALSO READShilpa Medicare gets EIR from USFDA for Jadcherla facility Shilpa Medicare receives EIR report for facility in Jadcherla in Telangana Shilpa Medicare consolidated net profit rises 73.94% in the June 2017 quarter Shilpa Medicare consolidated net profit declines 10.70% in the September 2017 quarter Shilpa Medicare standalone net profit rises 15.73% in the June 2017 quarter
Drug firm Shilpa Medicare today said it has received 10 observations from the US health regulator for its formulation facilities at Jadcherla in Telangana.
The company "has received 483 observations from the United States Food and Drug Administration (USFDA) in relation to SEZ formulation facilities situated at Jadcherla, Telangana," Shilpa Medicare said in a filing to the BSE.
Total 10 observations were cited during the close up meeting, it added.
While seven observations are regarding improvement in procedures and practises, three observations are related to setting of analytical specifications, test procedures and method validation, Shilpa Medicare said.
As per the USFDA, observations are made in Form 483 when investigators feel that conditions or practises in the facility are such that products may become adulterated or render injuries to health.
The FDA Form 483 notifies the company's management of objectionable conditions.
Shares of Shilpa Medicare today closed at Rs 635.15 per scrip on the BSE, down 0.24 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)